Novo Nordisk’s CEO Lars Fruergaard Jørgensen will stand down as the chief of the Danish pharma giant following increased ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...

CEO Lars Jørgensen is stepping down from his post after eight years in the role, during which he lead the company to an ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will resign due to the company's declining market position in obesity drugs. Despite previous successes with Wegovy, shares have dropped amid intense ...

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991. View on euronews ...

Novo Nordisk CEO Lars Fruergaard Jørgensen is stepping down as the Danish drug giant faces increased competition for its ...